ADDF Diagnostics Accelerator Funding for FTD Biomarker Development
Forecasted
This grant funds innovative research to develop new biomarkers for frontotemporal degeneration, aiming to enhance early and accurate diagnosis of FTD.
Funder: The Association for Frontotemporal Degeneration
Due Dates (Anticipated): June 2027 (Full application deadline, projected)
Funding Amounts: Recent awards range from $250,000–$1,200,000 per project; total program funding has reached ~$5 million.
Summary: Supports innovative research to develop biomarkers for frontotemporal degeneration (FTD), aiming to improve early and accurate FTD diagnosis.
Key Information: This is a forecasted opportunity; all dates are projected and may shift.
Description
This grant, offered by The Association for Frontotemporal Degeneration (AFTD) in partnership with the Alzheimer’s Drug Discovery Foundation (ADDF), is designed to accelerate the development of novel biomarkers for frontotemporal degeneration (FTD). Utilizing a venture philanthropy approach, the program supports high-potential, early-stage research that may not attract traditional commercial investment but holds promise for transforming FTD detection and monitoring. The ultimate goal is to enable earlier and more accurate diagnosis of FTD, thereby improving patient outcomes and advancing the field of neurodegenerative disease research.
